Business - Briefly   

DRL settles patent litigation with GlaxoSmithKline

HYDERABAD: Dr. Reddy's Laboratories announced on Tuesday that it has settled patent litigation with GlaxoSmithKline relating to sumatriptan succinate tablets, generic version of the latter's medicine. The terms of the settlement, which remain subject to Government review, provide that Dr. Reddy's may exclusively distribute an authorised generic version of sumatriptan succinate tablets (in 25 mg, 50 mg and 100 mg strengths) in the U.S. GlaxSmithKline's Imitrex tablets, which are indicated for acute treatment of migraine attacks in adults, had U.S. sales of $890 million for the period ending June 2006.

Printer friendly page  
Send this article to Friends by E-Mail

Stories in this Section

Sri Lankan Airlines in expansion mode
Dena Bank plans to sell NPAs worth Rs. 600 cr.
Goodyear rolls out state-of-the-art tyres
Initial gains not held on BSE
Mahindra keen on increasing market share
Gold merchants protest against VAT rate
Workshop on `knowledge management'
Cargo throughput at Kochi port increases marginally
Rupee drops further
UAE Exchange gets AD status
IFC to pick up stake in Suguna Poultry
Lalit Suri's demise a big blow to industry
Centre approves 34 more SEZs
Exchange rates
Bullion rates
Programme on information security management
Redington brings GenNext Microsoft Xbox 360
SpiceJet consolidates network
New Group Chief Executive for Aircel
DRL settles patent litigation with GlaxoSmithKline
Apache Design announces expansion plans
NIIT, Intel join hands
Steel majors to study future perspective
Moorat trading in BSE, NSE
Mahindra Auto in BSE indices
HSBC sells stake in IDFC
DCB IPO price fixed at Rs. 26

Copyright © 2006, The Hindu. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu